Skip to main content
K

FDA decision: Venglustat by Sanofi (in 2026)

Event Group
EventKALSHI
FDA decision: Venglustat by Sanofi (in 2026)
FDA decision: Venglustat by Sanofi (in 2026)
|
Vol

2.1K contracts

|
Markets

1

Market snapshot: Nov 19, 2026, 12:00 AM UTC. Prices may have changed.

Market Price Graph

1 market tracked

What will the FDA's decision be on Venglustat by Sanofi in 2026?

kalshi

No data available

All Markets(1)
MarketOutcome price
What will the FDA's decision be on Venglustat by Sanofi in 2026?
Yes 66.0%

Event Overview

FDA decision on Venglustat in 2026 If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach. This market will close early if the FDA issues a decision on Venglustat before Jan 1, 2027

Market Resolution Rules

If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach. Early close condition: This market will close early if the FDA issues a decision on Venglustat before Jan 1, 2027

Important Notes

  • Markets resolve based on official data sources specified in the rules
  • Resolution may be delayed if official data is not immediately available
  • Kalshi markets are regulated by the CFTC and follow strict resolution procedures
  • Always verify the exact resolution criteria before trading

Markets (1)

Sort
KALSHIHealth
What will the FDA's decision be on Venglustat by Sanofi in 2026?

What will the FDA's decision be on Venglustat by Sanofi in 2026?

If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach. Early close condition: This market will close early if the FDA issues a decision on Venglustat before Jan 1, 2027

Yes outcome66.0%
Yes
Volume2.1K contracts
LiquidityN/A
End DateJan 08, 2027
View Details

Share This Event

Share on social media or embed on your website